3dbs-lnbio Intestinal barrier model

About

MODEL 3DBS-LNBioIntestinalBarrier™

Model developed by LNBio – National Laboratory of Biosciences – CNPEM in partnership with 3DBS.

They are ideal for studies that test candidate drugs or biological products to treat diseases characterized by epithelial barrier lesions of the small intestine. In addition, nutrient absorption studies and ADMETox studies.

THE HUMAN SMALL INTESTINE IS A KEY PARAMETER TO DETERMINE THE BIOAVAILABILITY OF ORAL ADMINISTERED FORMULATIONS

A human model of intestinal barrier 3D in vitro that allows the evaluation of toxicity, metabolism, absorption of medicines and nutrients, the effects of oral formulations, and is a more predictive method for inflammatory processes, than traditional preclinical analyses with Caco-2. 

PRE-CLINICAL SCREENING

PREDICTION OF DRUG ABSORPTION AND ADVERSE EFFECTS

Studies with In Vitro models of intestinal barrier make it possible to evaluate the potential for drug absorption and the inflammatory process of the small intestine caused by new drug formulations. Preclinical screening using the intestinal barrier model allows researchers a clear view of the possible negative side effects of new drug formulations.MODELO 3DBS-LNBioIntestinalBarrier™

MODEL 3DBS-LNBioIntestinalBarrier™

We have developed alternative intestinal barrier models to replace animal guinea pigs, providing the need for safety and efficacy assessment tests of topical products such as medicines, cosmetics and food.

Inspired by the structures of nature, our goal is to enable the reconstruction of biomimetic tissues and organs that act as native tissues.

The 3DBS-LNBioIntestinalBarrier™ model is inserted in culture plates of 12 mm in diameter.

CHARACTERIZATION OF IMAGE DIFFERENTIATION

Intestinal barrier smouted with Hematoxylin & Eosin (H&E) after cuts of 5 to paraffin.

(A) Increase of 10x (B) 20x (C) 40x. 

CELLULAR VIABILITY

Measure of cell viability (%) of intestinal barriers over time, showing the high viability of barriers (greater than 80%) for up to 35 days after their biofabrication.

GENE EXPRESSION

Expression of markers of intestinal barrier function demonstrating the increase in expression in cell culture of B.I.3D, in relation to traditional 2D cultivation.

TRANSEPITHELIAL RESISTANCE

Measurement of transepithelial resistance during the differentiation of B.I. demonstrating that it has resistance as expected for a tissue.

Market segment:

Pharmaceutical, cosmetic, food industries. Research institutes, public and private universities

Use:

Only for research

APPLICATIONS:

Use the model 3DBS-LNBioIntestinalBarrierModel for:

  • Epithelial restitution: understand the mechanisms of wound healing in the intestine and evaluate therapeutic efficacy.
  • Intestinal fibrosis: induce human diseases and evaluate therapeutic efficacy.
  • Drug Metabolism and Drug Delivery: predictive and human-relevant drug delivery tests to assess permeation, flow and flow transport, as well as metabolism.
  • Inflammation: controlled in vitro cultivation conditions to induce human diseases and evaluate therapeutic efficacy.
  • Nutrient absorption: Studies to evaluate the absorption of nutrients of interest.
  • Organ on a chip: Studies that associate other models in vitro to evaluate interactions in micro fluidic systems.